N/A N=1,260,576 Improving Anticoagulation Control in VISN 1
Anticoagulants · Atrial Fibrillation · Venous Thromboembolism
Primary: Percent Change in Time in Therapeutic Range (TTR) — 2.8; 0.5 percent change — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=195 Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation
Ischemic Stroke · Transient Ischemic Attack
Primary: Number of Participants With Intracranial Bleeding and/or Recurrent Ischemic Lesion as Confirmed by MRI Imaging — 47; 48 Participants
N/A N=26 Strategies for Anticoagulation During Venovenous ECMO
Acute Hypoxemic Respiratory Failure · Anticoagulant-induced Bleeding · Thromboembolism
Primary: Number of Participants With Major Bleeding Events — 1; 4 Participants
Phase 4 N=21 Prophylaxis Regimen for Hemophilia A Patients
Hemophilia A · Prophylaxis of Bleeding
Primary: Overall Number of Participants With Favorable Outcome on the Score-assigned Prophylaxis Regimen — 12 participants
N/A N=25 Remote Home Prothrombin Time (PT)/International Normalized Ratio (INR) Monitoring and Patient Management System
Venous Thromboembolism
Primary: Time Spent Per PT/INR Monitoring Encounter — 19.4; 47 minutes
N/A N=200 Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care
Management of Anticoagulation
Primary: Mean Percentage of Time in Therapeutic Range — 48; 53 percentage of time — p=0.20
Phase 4 N=94 Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
COVID-19 · Venous Thromboses · Arterial Thrombosis
Primary: Total Number of Patients Who Were Alive and Without Venous/Thrombotic Events in ICU — 28; 31 Participants
Phase 3 N=1,351 Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Thrombocytopenia
Primary: At Least One Day With Grade 2 or Higher Bleeding — 304; 293; 299; 142 participants — p=0.83
N/A N=18 Observational Study of Citrate Based Dialysis in Pediatric Patients Receiving Hemodialysis
Complication of Dialysis
Primary: Dialyzer Clotting Rate — 6 percentage of total treatments
N/A N=100 Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation
Bradycardia · Tachycardia · Atrial Fibrillation
Primary: Bleeding Complication — 0; 2; 0; 2 participants
Phase 4 N=59 Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Atrial Fibrillation
Primary: Number of Days on Anticoagulation — 24.9 days
N/A N=72 Efficacy of a Health Belief Model Based Intervention for Anticoagulation Adherence
Anticoagulants
Primary: The Short-form Adherence to Refills and Medications Scale (ARMS) — 9.6; 9.4; 8.5; 9.3 score on a scale
Phase 4 N=101 Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation
Dementia · Cognition Disorders · Cerebral Ischemic Events
Primary: Number of Participants With Incident Dementia Determined by a Formal Diagnosis of Dementia by a Neurologist — 0; 0 Participants
N/A N=120,722 Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a Type of Irregular Heart Rhythm) at Higher Chance of Bleeding
Non-valvular Atrial Fibrillation
Primary: Incidence Rate Per 1000 Participant-Years For First Occurrence of Composite Stroke and Systemic Embolism (SE) Events After Index Date: Balanced Cohorts — 61.352; 75.078…
N/A N=748 D-Dimer Determined Anticoagulation INTENSITY in Patients With Mechanical Valve Replacement
Heart Valve Disease
Primary: Bleeding Events; — 16; 3; 4 Participants